Arcutis Biotherapeutics, Inc. Common Stock Profile
About
Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California.
Info & Links
CEO
Todd Franklin Watanabe
Headquarters
3027 TOWNSGATE ROAD, SUITE 300 WESTLAKE VILLAGE, CA 91361, UNITED STATES
Arcutis Biotherapeutics, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
2.11B
Enterprise Value
2.15B
Enterprise Value/EBITDA(ttm)
-25.47
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
7.70
Price to Book(mrq)
14.52
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
88.86%
Operating Margin(ttm)
-35.40%
Profit Margin(ttm)
-41.37%
Return on Equity(ttm)
-62.62%
Return on Invested Capital(ttm)
-36.41%
Return on Assets(ttm)
-25.16%
Income Statement
Revenue(ttm)
263.47M
Revenue Per Share(ttm)
2.20
Gross Profit(ttm)
234.74M
EBITDA(ttm)3
-84.41M
Net Income Available to Common(ttm)
-93.27M
Diluted EPS(ttm)
-0.75
Share Statistics
Beta (5Y Monthly)
1.93
52-Week Change
73.58%
S&P 500 52-Week Change
17.09%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
119.91M
Dividend Yield
0.00%
Float4
108.63M
% Held by Insiders
9.40%
% Held by Institutions
--
Balance Sheet
Total Cash(mrq)
191.13M
Total Cash Per Share(mrq)
1.59
Total Debt(mrq)
108.05M
Total Debt/Equity(mrq)
77.75%
Current Ratio(mrq)
3.20%
Quick Ratio(mrq)
3.04%
Book Value Per Share(mrq)
1.16
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.24
Free Cash Flow(ytd)
-30.74M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.